MCID: ANG046
MIFTS: 46

Angioimmunoblastic T-Cell Lymphoma

Categories: Rare diseases, Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Angioimmunoblastic T-Cell Lymphoma

MalaCards integrated aliases for Angioimmunoblastic T-Cell Lymphoma:

Name: Angioimmunoblastic T-Cell Lymphoma 49 55 51
Immunoblastic Lymphadenopathy 49 55
T-Cell Lymphoma, Aild Type 49 55
Lymphogranulomatosis X 49 55
Angioimmunoblastic Lymphadenopathy 69
Aitl 49
Ailt 55

Characteristics:

Orphanet epidemiological data:

55
angioimmunoblastic t-cell lymphoma
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 55 ORPHA86886
UMLS via Orphanet 70 C0020981
ICD10 via Orphanet 33 C86.5
ICD10 32 C86.5
UMLS 69 C0020981

Summaries for Angioimmunoblastic T-Cell Lymphoma

MalaCards based summary : Angioimmunoblastic T-Cell Lymphoma, also known as immunoblastic lymphadenopathy, is related to diffuse large b-cell lymphoma and b-cell lymphomas, and has symptoms including exanthema An important gene associated with Angioimmunoblastic T-Cell Lymphoma is BCL6 (B Cell CLL/Lymphoma 6), and among its related pathways/superpathways are IgA-Producing B Cells in the Intestine and MECP2 and Associated Rett Syndrome. The drugs Beleodaq and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotype is immune system.

Related Diseases for Angioimmunoblastic T-Cell Lymphoma

Diseases related to Angioimmunoblastic T-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Related Disease Score Top Affiliating Genes
1 diffuse large b-cell lymphoma 30.7 BCL6 MME
2 b-cell lymphomas 30.4 BCL6 MME
3 follicular lymphoma 30.0 BCL6 MME
4 angioimmunoblastic lymphadenopathy with dysproteinemia 11.6
5 lymphoma 11.2
6 peripheral t-cell lymphoma 10.5
7 autoimmune lymphoproliferative syndrome, type v 10.3
8 leukemia 10.3
9 gallbladder lymphoma 10.2 BCL6 MME
10 heart lymphoma 10.2 BCL6 MME
11 intravascular large b-cell lymphoma 10.2 BCL6 MME
12 testicular lymphoma 10.2 BCL6 MME
13 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
14 pure red-cell aplasia 10.1
15 pneumonia 10.1
16 vasculitis 10.1
17 plasma cell leukemia 10.1
18 t-cell/histiocyte rich large b cell lymphoma 10.1 BCL6 MME
19 marginal zone b-cell lymphoma 10.1 BCL6 MME
20 mature b-cell neoplasm 10.1 BCL6 MME
21 folic acid deficiency anemia 10.1 MME TET2
22 spondyloarthropathy 1 10.1
23 leukemia, chronic lymphocytic 2 10.1
24 leukemia, chronic lymphocytic 10.1
25 mycosis fungoides 10.1
26 myelofibrosis 10.1
27 polyarteritis nodosa, childhood-onset 10.1
28 arthritis 10.1
29 hematopoietic stem cell transplantation 10.1
30 thrombocytopenia 10.1
31 cardiac tamponade 10.1
32 inflammatory spondylopathy 10.1
33 cervicitis 10.1
34 spondylitis 10.1
35 polyarteritis nodosa 10.1
36 hypereosinophilic syndrome 10.1
37 leukemia, b-cell, chronic 10.1
38 endotheliitis 10.1
39 methotrexate-associated lymphoproliferative disorders 10.1
40 burkitt lymphoma 10.1 BCL6 CXCL13
41 lymphoblastic lymphoma 10.1 BCL6 MME
42 nephrogenic adenofibroma 10.0 MAF MME
43 breast papillary carcinoma 10.0 IDH2 MME
44 blood group, i system 9.9
45 systemic lupus erythematosus 9.9
46 rheumatoid arthritis 9.9
47 scleroderma, familial progressive 9.9
48 anemia, autoimmune hemolytic 9.9
49 ascites, chylous 9.9
50 lymphoma, hodgkin, classic 9.9

Graphical network of the top 20 diseases related to Angioimmunoblastic T-Cell Lymphoma:



Diseases related to Angioimmunoblastic T-Cell Lymphoma

Symptoms & Phenotypes for Angioimmunoblastic T-Cell Lymphoma

UMLS symptoms related to Angioimmunoblastic T-Cell Lymphoma:


exanthema

MGI Mouse Phenotypes related to Angioimmunoblastic T-Cell Lymphoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.1 BCL6 CXCL13 ITK MAF MME TET2

Drugs & Therapeutics for Angioimmunoblastic T-Cell Lymphoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Beleodaq 17 45 BELINOSTAT Spectrum Pharmaceuticals July 2014

Drugs for Angioimmunoblastic T-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 341)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
5
Methotrexate Approved Phase 4,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
6
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
7
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
8
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
9
Etoposide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
10
Ifosfamide Approved Phase 4,Phase 1,Phase 2 3778-73-2 3690
11
Mechlorethamine Approved, Investigational Phase 4,Phase 1,Phase 2 51-75-2 4033
12
Epirubicin Approved Phase 4 56420-45-2 41867
13
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 1,Phase 2 31703
16
Pirarubicin Investigational Phase 4 72496-41-4
17 Dexamethasone acetate Phase 4,Phase 3,Phase 2 1177-87-3
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
20 Folic Acid Antagonists Phase 4,Phase 2,Phase 1,Early Phase 1
21 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
24 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Vitamin B Complex Phase 4,Phase 2,Phase 1,Early Phase 1
26 Hormones Phase 4,Phase 3,Phase 1,Phase 2
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
28 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
32 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1,Phase 2
36 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 BB 1101 Phase 4,Phase 3,Phase 2
38 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Isophosphamide mustard Phase 4,Phase 1,Phase 2 0
40 Etoposide phosphate Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
41 Folate Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1
42 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 1,Early Phase 1
43
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
44
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
45
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
46
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
47
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
48
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
49
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
50
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 248)

# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Recruiting NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
3 Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP Unknown status NCT00725231 Phase 3 chemotherapy
4 Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00078949 Phase 3 cisplatin;cytarabine;dexamethasone;gemcitabine hydrochloride
5 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
6 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
7 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
8 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
15 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
16 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
17 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
18 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
19 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
20 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
21 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
22 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
23 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma Unknown status NCT00958854 Phase 2 cyclophosphamide;fludarabine phosphate;thalidomide
24 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
25 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
26 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
27 Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
28 Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
29 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymp Completed NCT02273739 Phase 1, Phase 2 AG-221
30 A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma Completed NCT00169156 Phase 2 Rituximab;Prednisone;Doxorubicine;Cyclophosphamide;Vincristine
31 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Completed NCT01336933 Phase 2 prednisone;cyclophosphamide;etoposide;vincristine sulfate;pralatrexate
32 RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas Completed NCT01198665 Phase 1, Phase 2 RAD001 (Everolimus)
33 Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma Completed NCT00901147 Phase 2 panobinostat and bortezomib
34 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma Completed NCT01466881 Phase 2 Alisertib
35 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
36 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
37 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
38 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
39 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
40 506U78 in Treating Patients With Lymphoma Completed NCT00005080 Phase 2 nelarabine
41 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
42 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
43 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
44 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
45 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
46 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
47 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
48 Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma Completed NCT00039351 Phase 2 cyclophosphamide;prednisone;vincristine sulfate
49 Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment Completed NCT00436618 Phase 2 Everolimus
50 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2

Search NIH Clinical Center for Angioimmunoblastic T-Cell Lymphoma

Genetic Tests for Angioimmunoblastic T-Cell Lymphoma

Anatomical Context for Angioimmunoblastic T-Cell Lymphoma

MalaCards organs/tissues related to Angioimmunoblastic T-Cell Lymphoma:

38
T Cells, Bone, Bone Marrow, B Cells, Liver, Kidney, Breast

Publications for Angioimmunoblastic T-Cell Lymphoma

Articles related to Angioimmunoblastic T-Cell Lymphoma:

(show top 50) (show all 335)
# Title Authors Year
1
Bone Marrow Involvement of Epstein-Barr Virus-Positive Large B-Cell Lymphoma in a Patient with Angioimmunoblastic T-Cell Lymphoma. ( 29214764 )
2018
2
Emergence of anti-mitochondrial M2 antibody in patient with angioimmunoblastic T-cell lymphoma. ( 29428971 )
2018
3
Florid Plasmacytosis in Angioimmunoblastic T Cell Lymphoma: A Diagnostic Conundrum. ( 29398831 )
2018
4
Epstein-Barr virus clonality and plasmacytosis in a patient with atypical angioimmunoblastic T cell lymphoma. ( 29189897 )
2018
5
A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma. ( 29048103 )
2018
6
Identification of autofluorescent cells in human angioimmunoblastic T-cell lymphoma. ( 29197996 )
2018
7
Mutational heterogeneity of angioimmunoblastic T-cell lymphoma indicates distinct lymphomagenic pathways. ( 29339730 )
2018
8
Expression of Master Regulators of T-cell, Helper T-cell and Follicular Helper T-cell Differentiation in Angioimmunoblastic T-cell Lymphoma. ( 28943543 )
2017
9
Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling. ( 28148900 )
2017
10
A Rare Case of Angioimmunoblastic T-Cell Lymphoma with Epstein-Barr Virus-Negative Reed-Sternberg-Like B-Cells, Chylous Ascites, and Chylothorax. ( 28487786 )
2017
11
Angioimmunoblastic T-Cell Lymphoma Mimicking Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome). ( 28611626 )
2017
12
TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. ( 28337768 )
2017
13
Detection of the circulating tumor DNAs in angioimmunoblastic T- cell lymphoma. ( 28634614 )
2017
14
Image Gallery: Generalized annular figurate erythema as an unusual presentation of angioimmunoblastic T-cell lymphoma. ( 28940282 )
2017
15
Angioimmunoblastic T-cell Lymphoma Associated with IgA Nephropathy. ( 28050005 )
2017
16
Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. ( 28832024 )
2017
17
Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. ( 28082343 )
2017
18
Angioimmunoblastic T-Cell Lymphoma. ( 28340875 )
2017
19
Invasive aspergillosis in Refractory Angioimmunoblastic T cell lymphoma. ( 29129826 )
2017
20
Angioimmunoblastic T-Cell Lymphoma: A Questionable Association with Follicular Dendritic Cell Sarcoma. ( 28197348 )
2017
21
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. ( 29100307 )
2017
22
A review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma. ( 28889481 )
2017
23
Cardiac Tamponade as Initial Presentation of Angioimmunoblastic T-Cell Lymphoma. ( 28481741 )
2017
24
Angioimmunoblastic T-cell lymphoma: more than a disease of T follicular helper cells. ( 28543514 )
2017
25
Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. ( 28194275 )
2017
26
Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. ( 28512625 )
2017
27
Two cases of angioimmunoblastic T-cell lymphoma with concomitant positive serology for acute Epstein-Barr virus infection. ( 29071053 )
2017
28
Angioimmunoblastic T Cell lymphoma mimics reactive lymphoid tissue on cytomorphology: A multimodality approach utilising cytology, immunocytochemistry and flow cytometry to resolve this diagnostic dilemma. ( 28370552 )
2017
29
Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas. ( 28945625 )
2017
30
Clinical characteristics of angioimmunoblastic T-cell lymphoma in China and C-reactive protein as an independent prognostic factor. ( 28953629 )
2017
31
Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. ( 29279549 )
2017
32
Death caused by possible unrecognized (too Late Recognized) Mycobacterium gordonae infection in a patient with angioimmunoblastic T-cell lymphoma. ( 28559527 )
2017
33
Angioimmunoblastic T-cell lymphoma and hypereosinophilic syndrome with FIP1L1/PDGFRA fusion gene effectively treated with imatinib: A case report. ( 28885361 )
2017
34
Expression of the significance of silent information regulator type-1 in Angioimmunoblastic T-cell lymphoma is greater association with tumorigenesis and has strong implications for adverse prognosis. ( 27124741 )
2016
35
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. ( 27983760 )
2016
36
A difficult case of angioimmunoblastic T-cell lymphoma to diagnose. ( 26969779 )
2016
37
p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. ( 26915336 )
2016
38
Clinical features, outcome and prognostic factors of 87 patients with angioimmunoblastic T cell lymphoma in Taiwan. ( 27095042 )
2016
39
Pneumocystis pneumonia associated with peripheral lymphocytosis in angioimmunoblastic T-cell lymphoma, resembling immune reconstitution syndrome. ( 27544629 )
2016
40
Molecular mechanisms of angioimmunoblastic T-cell lymphoma development. ( 27599421 )
2016
41
Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. ( 26998168 )
2016
42
Cutaneous Presentation of Angioimmunoblastic T-Cell Lymphoma: A Harbinger of Poor Prognosis? ( 28031140 )
2016
43
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320. ( 27001186 )
2016
44
Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient. ( 26984089 )
2016
45
A Case of Cutaneous Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma in an Angioimmunoblastic T-Cell Lymphoma. ( 27904290 )
2016
46
Elevated absolute monocyte count predicts unfavorable outcomes in patients with angioimmunoblastic T-cell lymphoma. ( 26764222 )
2016
47
Angioimmunoblastic T Cell Lymphoma Mimicking Chronic Urticaria. ( 26925107 )
2016
48
Discussion of 18F-FDG PET/CT imaging characteristics and diagnostic values of angioimmunoblastic T-cell lymphoma. ( 27832711 )
2016
49
Expression of multiple cytokines and chemokine receptor 4 in angioimmunoblastic T-cell lymphoma with abundant plasma cell infiltration involving the skin. ( 27072191 )
2016
50
Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology. ( 27105079 )
2016

Variations for Angioimmunoblastic T-Cell Lymphoma

Expression for Angioimmunoblastic T-Cell Lymphoma

Search GEO for disease gene expression data for Angioimmunoblastic T-Cell Lymphoma.

Pathways for Angioimmunoblastic T-Cell Lymphoma

Pathways related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.08 BCL6 CXCL13
2 10.95 BCL6 TET2
3 10.68 BCL6 MME
4
Show member pathways
9.74 IDH2 TET2

GO Terms for Angioimmunoblastic T-Cell Lymphoma

Biological processes related to Angioimmunoblastic T-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.33 BCL6 CXCL13 ITK
2 cytokine production GO:0001816 8.96 ITK MAF
3 germinal center formation GO:0002467 8.62 BCL6 CXCL13

Sources for Angioimmunoblastic T-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....